Global Chemotherapy Drug Market, By Type (Alkylating Agents, Anti-metabolites, Plant Alkaloids and Terpenoids, Podophyllotoxin, Taxanes, Topoisomerase Inhibitor, Anti-Tumour Antibiotics, Hormones, Monoclonal Antibodies, Others), Indication (Oncology/Cancer, Bone Marrow Diseases, Immune System Disorders, Others), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Cancer is the second biggest cause of mortality worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018. As cancer rates rise, so will demand for chemotherapy medications. Chemotherapy is a type of cancer treatment in which medications are used to kill a large number of rapidly developing cells in the body. Chemotherapy is effective in reducing the number of cancer cells in the body, slowing cancer progression, and shrinking tumors.
Data Bridge Market Research analyses that the chemotherapy drug market was valued at USD 42,909.37 million in 2021 and is expected to reach USD 89,338.07 million by 2029, registering a CAGR of 9.60% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Alkylating Agents, Anti-metabolites, Plant Alkaloids and Terpenoids, Podophyllotoxin, Taxanes, Topoisomerase Inhibitor, Anti-Tumour Antibiotics, Hormones, Monoclonal Antibodies, Others), Indication (Oncology/Cancer, Bone Marrow Diseases, Immune System Disorders, Others), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Chemotherapy is the most common type of cancer treatment drug. Chemotherapy is used to slow or stop the growth of cancer cells. Chemotherapy primarily targets malignant cells that are rapidly developing. Chemotherapy is the use of a chemical substance to stop cancer cells from growing. Chemotherapy medications come in a variety of forms. Adriamycin, Taxotere, Ellence, Paraplatin, Taxol, Cytoxan, Navelbine, Ixempra, Xeloda, Abraxane, Gemzar, and Halaven are some of the chemotherapy medications commonly used for adjuvant and neoadjuvant chemo. All of these chemotherapy medicines target various stages of the cell cycle. Drugs can be given as monotherapy or in combination therapy during chemotherapy.
Chemotherapy Drug Market Dynamics
Drivers
- Increasing prevalence of cancer
The rising prevalence of cancer is estimated to enhance the chemotherapy drug market's growth rate. Cancer is the greatest cause of mortality worldwide, according to the World Health Organization (WHO), accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Around 400 000 children are diagnosed with cancer every year. Cervical cancer is the most frequent cancer in 23 of the world's countries. Chemotherapy is the most common cancer treatment, and it is often used in conjunction with other cancer treatments. Neo-adjuvant chemotherapy is chemotherapy provided before surgery and radiation therapy to shrink the tumor cell, whereas adjuvant chemotherapy is chemotherapy administered after surgery or radiation therapy to shrink the tumor cell.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of chemotherapy drug market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising geriatric population and rise in demand for advanced cancer drugs will expand the chemotherapy drug market. Additionally, growing awareness about chemotherapy coupled with increasing number of patients undergoing chemotherapy and radiotherapy treatments are estimated to enhance the market’s growth rate.
Opportunities
- Development of innovative technology
Chemotherapy has played a critical role in prolonging the lives of cancer patients for a few years longer than they would have lived otherwise. The most recent advancement in the chemotherapy field involves injecting cancer-fighting medications (customized nanoparticles) into contaminated areas without harming healthy cells. This method has been shown to eliminate malignant cells while maintaining healthy tissue. Doctors use photon lasers to track when these nanoparticles (with tubes and pores) are released in a patient's body and study the duration and spread of these medications to kill malignant cells. The University of California, Los Angeles, is now conducting a clinical trial of this approach, which has shown to be beneficial in treating lower-stage cancer patients and is set to enter the chemotherapeutic market in the near future.
- Increase in the number of research and development activities
The chemotherapy drug market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the chemotherapy drug market growth.
Moreover, increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the chemotherapy drug market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the chemotherapy drug will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the chemotherapy drug market. Additionally, side effects of chemotherapy drugs such as heart problems, decreased red blood cell count, fatigue, weight loss, loss of hair, diarrhea, weight loss, decreased lung, kidney, and liver quality and reduced bone density and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This chemotherapy drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chemotherapy drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Chemotherapy drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Chemotherapy Drug Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. In November of 2019, the globe was shocked to learn of the COVID-19 virus. In previous years, there was no medical understanding or hint of such a virus that may have prepared the world to deal with the infection's criticality. Lockdowns were ordered by governments all around the world to stop the virus from spreading. When tested against SARS-CoV-2, chemotherapy medications such azithromycin, omycin, and pralatrexate, which are used to treat lymphoma, showed progressive results in eliminating COVID-19 virus. Manufacturers of chemotherapy drugs have benefitted in COVID-19 times by investing in corona research initiatives, and they are anticipated to gain popularity and success in effective corona treatment.
Recent Development
- In May 2022, Gland Pharma had announced the launch of Bortezomib for Injection in US market. Bortezomib for injection is employed for treating certain types of cancer including multiple myeloma and mantle cell lymphoma.
Global Chemotherapy Drug Market Scope
The chemotherapy drug market is segmented on the basis of indication, type, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Oncology/Cancer
- Bone Marrow Diseases
- Immune System Disorders
- Others
Type
- Alkylating Agents
- Anti-metabolites
- Plant Alkaloids and Terpenoids
- Podophyllotoxin
- Taxanes
- Topoisomerase Inhibitor
- Anti-Tumour Antibiotics
- Hormones
- Monoclonal Antibodies
- Others
Dosage Forms
- Capsule
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Others
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Chemotherapy Drug Market Regional Analysis/Insights
The chemotherapy drug market is analysed and market size insights and trends are provided by country, indication, type, dosage forms, route of administration, end-users and distribution channel as referenced above.
The countries covered in the chemotherapy drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the chemotherapy drug market because of the presence of key manufacture of the product and rising geriatric population in this region. Additionally, high research and development expenditure and presence of skilled professionals will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, growing number of generic drugs will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Chemotherapy Drug Market Share Analysis
The chemotherapy drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chemotherapy drug market.
Some of the major players operating in the chemotherapy drug market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-
